Ace Inhibitors Market: Historical, Current and Projected Market Size, Competitive landscape & Forecast 2025

ACE Inhibitors Market: Information by Drug (Lisinopril, Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril and  others), Application (Heart Failure, Hypertension, Diabetes, Heart Attack, Chronic Kidney Disease and others), Dosage Form (Oral Tablets and Oral Solution), Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-commerce Websites and Online Drug Stores) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2025

Market Highlights

According to MRFR analysis, ACE Inhibitors Market is expected to register a CAGR of 3.10% during the forecast period of 2019 to 2025 and is likely to be valued at USD 7682.8 Million in 2025.  

The growth of the global ACE inhibitors market is determined by numerous factors such as rising adoption of ACE inhibitors for the treatment of cardiovascular complications and diabetic neuropathy, rising cases of cardiovascular disorders such as hypertension, and surge in demand for less expensive drugs. For instance, according to the data published by the World Health Organization (WHO) in 2017, the global prevalence rate of raised blood pressure in adults aged more than 18 was estimated to be 22.1% in 2017. However, side effects associated with the treatment and high costs of treatment are likely to hamper the growth of the global ACE inhibitors market during the forecast period. 

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

Americas has been segmented into North America and Latin America, with the North American market being divided into the US and Canada. The Americas is projected to hold the largest market share owing to the growing prevalence of hypertension and cardiovascular disorders.       

The European ACE inhibitors market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The ACE inhibitors market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The presence of a huge population base, increasing awareness about cardiovascular disorders, and rising disposable income are the key factors responsible for the fastest growth of the market in Asia-Pacific. The ACE inhibitors market in the Middle East & Africa has been divided into the Middle East and Africa.

Segmentation

The Global ACE Inhibitors Market has been segmented based on Product, Application, Dosage Form, and Distribution Channel.

The market, based on product, has been divided into lisinopril, ramipril, enalapril, benazepril, fosinopril, captopril, moexipril, and others. The lisinopril is likely to hold the maximum market share in the global ACE inhibitors market owing to the growing adoption of lisinopril in the management of cardiovascular complications and diabetic neuropathy.

The global ACE inhibitors market based on the application has been segregated into heart failure, hypertension, diabetes, heart attack, chronic kidney disease, and others. The hypertension segment is expected to hold a larger share of the market share owing to the rising cases of hypertension and the adoption of ACE inhibitors.

The dosage form segment of the market is divided into oral tablets and oral solution. Capoten, Vasotec, Prinivil, Zestril, Lotensin, Monopril, and Altace are some well-known and widely used oral tablets.

Based on distribution channel, the global ACE inhibitors market has been segmented into retail pharmacy, hospital pharmacy, e-commerce websites and online drug stores, and others. Retail pharmacy holds maximum market share during the forecast period.

Access Report Details @ https://www.marketresearchfuture.com/reports/ace-inhibitors-market-8631

Key Players

Some of the Key Players in the Global ACE Inhibitors Market are Bristol-Myers Squibb Company (US), Par Pharmaceutical Companies, Inc. (US), UCB, Inc. (Belgium), Pfizer, Inc.(US), AbbVie Inc.(US), AstraZeneca (UK), Bausch Health Companies Inc.(Canada), Novartis AG (Switzerland), Merck & Co., Inc.(US), Teva Pharmaceutical Industries Ltd.(Israel), Silvergate Pharmaceuticals, Inc. (US), and others.

Antiemetics Market Overview, Dynamics, Supply & Demand, Analysis & Forecast by 2025

Market Highlights

According to MRFR analysis, Antiemetics Market is expected to register a CAGR of 6.6% during the forecast period of 2019 to 2025 and account for USD 6.7 Billion in 2025.

The Global Antiemetics Market is expected to grow at a steady pace. There are numerous antiemetics agents available for the treatment of nausea and vomiting, including; dopamine antagonists, anticholinergics, antihistamines, serotonin antagonists, and others. The key players manufacturing these products include GSK, Merck, and Pfizer Inc. As these players generate their maximum revenue from the Americas for the market, the region accounted for significant share across the globe.

The market is expected to grow at a steady growth rate. The significant factors influencing the growth of the market include increasing investment in the pharmaceutical industry, increasing the number of postoperative procedures, pregnancy-induced nausea, and acute gastroenteritis, further influencing the growth of the market. Moreover, the rising demand for novel therapeutics and the increasing prevalence of postoperative nausea and vomiting (PONV) is responsible for positive market growth.  

Segmentation

The Global Antiemetics Market has been segmented into agents, drug type, application, and distribution channel.

By agents, the market has been segmented into dopamine antagonists, anticholinergics, antihistamines, serotonin antagonists, cannabinoids, and others. Furthermore, dopamine antagonists is segmented into phenothiazines (chlorpromazine, prochlorperazine), butyrophenones (droperidol, domperidone ), and benzamides. Moreover, serotonin antagonists is further divided into ondansetron, granisetron. The others segment includes dexamethasone and propofol. Dopamine accounted for the largest market share majorly due to FDA approval for the maximum number of application

By drug type, the market is segmented into prescribed and OTC. Prescribed drugs accounted for the large share by drugs type due to the high cost of the drugs when compared to OTC and also are most prescribed by the professionals.

Based on application, the market is segmented into chemotherapy, motion sickness, stomach flu, pregnancy, postoperative surgery, and others. Postoperative surgery accounted for the largest market share on the basis of attributing to an increasing number of surgery procedures and mandatory postoperative procedures for the same.

The global antiemetics market, by distribution channel, has been a retail pharmacy, hospital pharmacy, online. On the basis of distribution channel, retail pharmacies accounted for the largest share due to the presence of a large number of retail pharmacies across the globe.

Key Players

Some of the key players in the Global Antiemetics Market are GSK (UK), Merck (US), Sanofi-Aventis (France), Pfizer Inc. (US), Mylan (US), Eli Lilly and Company (US), Johnson & Johnson (US), Baxter International (US), Dr. Reddy's Laboratories Inc. (India) and others.

Browse Full Report Details @ https://www.marketresearchfuture.com/reports/antiemetics-market-8454

Regional Analysis

On a regional basis, the Americas are anticipated to dominate the global antiemetics market owing to the growing clinical research & development budgets by both public and private organizations in the pharmaceutical industry, increasing demand for novel therapeutics and the abundant presence of significant manufacturer in the region. Additionally, rising postoperative procedures is expected to influence the growth of the market. According to a study, it is found that PONV occurs in nearly 30% of the general surgical population and up to 70% to 80% of high-risk surgical patients. Europe is expected to account for the second-largest market in the global antiemetics market owing to well-developed research infrastructure, increasing healthcare awareness in the region, and high expenditure in pharmaceutical research.

Moreover, rising healthcare expenditure is boosting the market in this region. Asia-Pacific is expected to be the fastest-growing region due to the growing interest of major key players in entering emerging markets, increasing development in the pharmaceutical industry in this region. Moreover, increasing the adoption of chemotherapy for the treatment of cancer expected to influence the growth of the market. The Middle East & Africa is expected to account for the least share of the global antiemetics market. Moreover, the significant market share of the region is expected to be held by the Middle East region owing to the increasing investment by major manufacturers and changing healthcare reforms.

bronchodilators market 2019-2025: Market Opportunities, Competitive Landscape, Segmentation, Analysis & Forecast

Market Highlights

According to MRFR analysis, Bronchodilators Market is expected to register a CAGR of 5.30% during the forecast period of 2019 to 2025 and is expected to reach USD 2,484 Million by 2025.

Bronchodilators are medications that make breathing easier by opening the airways of the lung by relaxing bronchial muscles. They are used to treat various respiratory problems such as asthma, COPD, and other allergic reactions that cause breathing problems.

The growth of the global bronchodilators market is driven by various factors such as increase in prevalence of pulmonary disorders, increasing geriatric population and increasing mergers and acquisitions by prominent players in the market. However, side effects associated with bronchodilators and government regulations related to the safety & efficacy of the bronchodilators are projected to hamper the growth of the global bronchodilators market.

The global bronchodilators market is currently dominated by several market players. The key players are involved in product launches and strategic collaborations to strengthen their market positions. For instance, in April 2019, Cipla Technologies entered into agreement with Pulmatrix Inc. to co-develop a formulation for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma.

Segmentation

The global bronchodilators market has been segmented based on drug type, disease, mode of action, and route of administration.

The market, based on drug type, has been divided into adrenergic drugs, anticholinergics, a phosphodiesterase inhibitor, and combination drugs.

The adrenergic segment is likely to be the largest during the review period as they are the most potent bronchodilators approved for clinical use in asthma and obstructive lung disease. The combination drugs segment is predicted to be the fastest-growing segment. These combination drugs are used if COPD and asthma are not controlled with monotherapy. These combinations involving two long-acting bronchodilators with differing modes of action.

The global bronchodilators market has been segmented, on the basis of disease, into asthma, COPD, and others. The asthma segment is expected to hold the majority share of the market, owing to the rise in patients affected with asthma. The COPD segment is expected to be the fastest-growing as bronchodilators are primary treatment for chronic obstructive pulmonary disease (COPD) as they help to alleviate bronchial obstruction and airflow limitation.

In terms of mode of action, the global bronchodilators market has been segmented into short-acting bronchodilators and long-acting bronchodilators. Short-acting bronchodilators are expected to be the largest segment, owing to its ability to provide quick relief from sudden, unexpected attacks of breathlessness.

The route of administration of the market is oral and parenteral. The oral route of administration segment is expected to hold the largest share of the market due to the advantages such as ease and simplicity of administration along with control of delivered dose.

Key Players

Some of the key players in the Global Bronchodilators Market are GlaxoSmithKline (UK), Novartis AG (Switzerland), Merck & Co., Inc. (US), Abbott Laboratories (US), Boehringer Ingelheim GmbH (Germany), AstraZeneca plc (UK), F. Hoffmann LA-Roche AG (Switzerland), Teva Pharmaceutical (Israel) and Pfizer Inc. (US) among others.

Access Report Details @ https://www.marketresearchfuture.com/reports/bronchodilators-market-8453

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas are expected to be the largest market owing to the rising per capita healthcare expenditure. The bronchodilators market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European bronchodilators market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The bronchodilators market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing prevalence of respiratory disorders and the increasing pool of patient population, the market in Asia-Pacific is expected to be the fastest-growing. The bronchodilators market in the Middle East & Africa has been divided into the Middle East and Africa.

Pharmacovigilance Market: Emerging Technologies, Competition & Strategies of Key Players, Regional Analysis and Forecast By 2025

Market Highlights

According to MRFR analysis, Pharmacovigilance Market is expected to register a CAGR of 14.1% during the forecast period of 2019 to 2025 and accounts for USD 4321.86 Million 2018.

Pharmacovigilance supports safe and appropriate use of drugs by identifying risk factors for the development of adverse drug reactions (ADR), promoting the detection of previously unknown ADR and their interactions with known ADR.

The market is dominated by numerous established players. The key players are involved in product launches and strategic collaborations to strengthen their market positions. For instance, on May 16, 2019, Accenture launched INTENT to improve the continuity and flow of data across life sciences enterprises, supporting the delivery of ground-breaking treatments for patients.

Segmentation

The Global Pharmacovigilance Market has been segmented based on the clinical trial phase, service provider, type, and end-user.

The market, based on the clinical trial phase, has been divided into phase IV, phase III, phase II, phase I, and pre-clinical. Phase IV segment dominated the pharmacovigilance market as adverse drug reactions are majorly detected in this phase. Whereas, phase III is expected to witness the fastest growth.

The global pharmacovigilance market has been segmented, on the basis of service provider, into in-house and contract outsourcing. Contract outsourcing dominated the global pharmacovigilance market and expected to witness the fastest growth. Contract manufacturing serves multiple customers and thus can acquire raw materials at a reduced cost, benefiting from the economies of scale.  

The market, based on type, has been divided into spontaneous reporting, cohort event monitoring, intensified ADR reporting, targeted spontaneous reporting, and EHR mining. The spontaneous reporting held largest market share in 2018. Spontaneous reporting is a passive approach to pharmacovigilance as it entirely relies on the motivation of individuals to report suspected ADRs to a local or national pharmacovigilance center.

In terms of end-user, the global pharmacovigilance market has been segmented into hospitals, research organizations, pharmaceutical companies, and others. Hospitals take up the largest share due to an increase in the number of hospital admissions due to ADRs.

Browse Full Report Details @ https://www.marketresearchfuture.com/reports/pharmacovigilance-market-8451

Key Players

Some of the key players in the Global Pharmacovigilance Market are Accenture (Ireland), ArisGlobal (US), BioClinica (US), Capgemini (France), Conquest Group BV (Netherlands), Cognizant (US), IBM Corporation (US), ICON PLC (Ireland), IMEDGlobal (US), ITClinical (Portugal), Laboratory Corporation of America Holdings (US), PAREXEL International Corporation (US), TAKE Solutions Ltd (India), United BioSource Corporation (US), and Wipro Ltd (India).

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to be the largest market owing to the high spending by the pharmaceutical industry. The pharmacovigilance market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European Pharmacovigilance market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The Pharmacovigilance market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing prevalence of chronic conditions and rising cases of ADRs and medication errors, the market in Asia-Pacific is expected to be the fastest-growing. The pharmacovigilance market in the Middle East & Africa has been divided into the Middle East and Africa.

Vision Care Market: Historical, Current and Projected Market Size, Competitive landscape & Forecast 2025

Market Highlights

According to MRFR analysis, Vision Care Market is expected to register a CAGR of 4.48% during the forecast period of 2019 to 2025 was valued at USD 52,000 Million in 2018.

Vision care plays an essential role in ophthalmology. The vision care products and procedures are used for treating the indications. For instance, the prevalence of vision impairment is about 1,000 million cases globally. The vision care has benefited resolve ophthalmic disorders and diseases.

However, unawareness about the vision care products and services is likely to hamper the growth of the global vision care market during the forecast period.

Several market players currently dominate the global vision care market. The key players are involved in product launches and strategic collaborations to strengthen their market positions.

Segmentation

The global vision care market has been segmented based on product type, indication, treatment, and end user.

The market, based on product type, has been divided into contact lenses, eyeglasses, intraocular lenses (IOL), and others. The contact lens segment has been further classified as corrective lens, therapeutic lens, cosmetic, and lifestyle-oriented lens. The contact lens is likely to hold the maximum market share in the global vision care market, owing to the unwillingness of people to use the eyeglasses. Eyeglasses are further segmented single vision, bifocal, progressive, sunglasses. The intraocular lens (IOL) segment is further segmented into Premium, Traditional/Mono-focal, Phakic.

The global vision care market on the basis of indication has been segregated into refractive error cataract, glaucoma, diabetic retinopathy, amblyopia, dry eyes, and others.

On the basis of treatment, the global vision care market is mainly segmented into Surgery, medication, and others.

The end user segment of the market consists of eye hospitals & clinics, ambulatory surgery centers, optical stores, and others. Optical stores segment is expected to hold the largest share of the market as these centers are primary locations for patients utilize the vision care products.

Browse Full Report Details @ https://www.marketresearchfuture.com/reports/vision-care-market-8450

Key Players

Some of the key players in the Global Vision Care Market are Cadila Healthcare (Zydus Pharmaceuticals, Inc.), Johnson & Johnson Services, Inc., Rayner Surgical Group Limited (Rayner Intraocular Lenses Limited), Menicon, Carl-Zeiss-Stiftung (Carl Zeiss). ESSILORLUXOTTICA, Bausch Health (Bausch & Lomb Incorporated), The Cooper Companies, Inc (Cooper Vision), NOVARTIS AG.

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas is anticipated to hold the largest market share owing to the increasing awareness about advanced vision care procedures. The vision care market is divided into the Americas has further been branched into North America and Latin America, with the North American market being divided into the US and Canada.

The vision care market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Asia-Pacific is anticipated to hold the largest market share owing to the increasing number of increasing geriatric population and rising adoption of technological advancements in developing regions. The European vision care market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The vision care market in the Middle East & Africa has been divided into the Middle East and Africa.

Intrauterine Contraceptive Devices Market Detailed Analysis, Growth Factors, Top Key Companies, Trends and Developments, 2019-2025

Market Highlights

According to MRFR analysis, Intrauterine Contraceptive Devices (IUCDs) Market is expected to register a CAGR of 10.5% during the forecast period of 2019 to 2025 and was valued at USD 1364.0 Million in 2018.

Contraceptive devices are used to prevent unwanted pregnancy by restricting the natural ovulation cycle or making changes in the egg fertilization process. Intrauterine contraceptive devices are placed inside the uterus to avoid unintended pregnancy. These devices contain a string which guarantees the precise placement of the device inside the uterus and provide aid in removal. lifespan of these devices varies as per the brands, and it can last up to 3,5 and 10 years. Plastic and metal are used in manufacturing of intrauterine contraceptive devices (IUCDs). It is available in several shapes, such as coil, loop, triangle, and T-shaped.

The growth of global intrauterine contraceptive devices (IUCDs) market is determined by numerous factors such as an increase in unintended pregnancies, technological advancements in the healthcare industry, and increasing government initiatives to spread awareness about birth control. However, the side effects associated with use of intrauterine contraceptive devices (IUCDs) and Stringent regulatory guidelines and strict reimbursement is likely to hamper the growth of the global intrauterine contraceptive devices (IUCDs) market during the forecast period.

Several market players currently dominate the global intrauterine contraceptive devices (IUCDs) market. The key players are involved in product launches and strategic collaborations to strengthen their market positions.

Access Report Details @ https://www.marketresearchfuture.com/reports/intrauterine-contraceptive-devices-market-8449

Segmentation

The global intrauterine contraceptive devices (IUCDs) market has been segmented based on type and end user.

The market, based on type, has been divided into a hormonal intrauterine device and copper intrauterine device. Copper intrauterine devices are likely to hold the maximum market share in the global intrauterine contraceptive devices (IUCDs) market.

The end user segment of the market consists of hospitals, gynecology clinics, community health care centers, and others. The hospitals segment is expected to hold the largest share of the market as these centers are the primary locations for patients receiving treatment and undergoing medical procedures.

Key Players

Some of the key players in the Global Intrauterine Contraceptive Devices (IUCDs) Market are Bayer AG, The Cooper Companies, Inc., Pfizer Inc., HLL Lifecare Limited, OCON Healthcare, SMB Corporation, Egemen International, EUROGINE, S.L., Meril Life Sciences Pvt. Ltd., Mona Lisa N.V., Prosan International B.V., Pregna International Limited, and Others.

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Asia-Pacific is anticipated to hold the largest market share. The intrauterine contraceptive devices (IUCDs) market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the presence of a large patient pool, developing the healthcare sector, and raising awareness about intrauterine contraceptive devices the region.

The Americas is anticipated to be the fastest-growing market owing to the rising number of unintended pregnancies, well-established healthcare sector, and increasing healthcare expenditure. The intrauterine contraceptive devices (IUCDs) market in the Americas has further been branched into North America and Latin America, with the North American market being divided into the US and Canada.

The European intrauterine contraceptive devices (IUCDs) market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The intrauterine contraceptive devices (IUCDs) market in the Middle East & Africa has been divided into the Middle East and Africa.

Intravascular Catheter Market: Historical, Current and Projected Market Size, Competitive landscape & Forecast 2023

Intravascular Catheter Market Research Report: Information by Product (Short PIVC Catheters and Integrated/Closed PIVC Catheters), Application (Renal Disease, Cancer, Gastrointestinal Diseases, Infectious Diseases and other Diseases), End User (Hospitals, Clinics, Ambulatory Surgical Centers, Homecare and others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2024

Market Insights

Market Research Future (MRFR) estimated that the global intravascular catheter market is set to attain a market value of USD 4, 318 million, with a CAGR of 9.3% during the forecast period (2019-2024).

The Global Intravascular Catheter Market is driven by some of the various factors, such as the rising rate of hospitalization owing to the growing prevalence of infectious diseases. The increasing number of catheterization laboratories is anticipated to propel the growth of the market.

On the other hand, lack of expertise and advanced medical infrastructure in developing nations is expected to restrain the growth of the global intravascular catheter market. The increasing number of surgeries for the patients under treatment for chronic diseases, rise in demand for invasive surgical procedures by using catheters at ambulatory surgical centers are some of the critical drivers propelling the growth of the global intravascular catheter market.

Inadequate quality assurance, volatile pricing, and limited reimbursement in various developing nations are some the restraining factor in the global market. Increased count of surgeries for treating gastroenterology, cardiovascular, renal, and other diseases is one of the critical pointers driving the global intravascular catheter market.

Market Segmentation

The global intravascular catheter market is broadly bifurcated on the basis of product, application, and end-user.

Based on the product, the global market is diversified into integrated/closed PIVC catheters and short PIVC catheters.

The application segment is divided into cancer, renal disease, infectious diseases, gastrointestinal diseases, and other diseases.

The global end-user segment is split into hospitals, clinics, ambulatory surgical centers, home care, and others

Browse Complete Report :https://www.marketresearchfuture.com/reports/intravascular-catheter-market-7966

Regional Insights

The global intravascular catheter market is dominated by the Americas, owing to a rise in per capita income, heavy adoption, and increased healthcare expenditure. Growing occurrences of hospital-acquired infection and the present of advanced healthcare facilities jointly foster the market growth in the North America region. Favorable reimbursement facilities related to intravascular catheters further motivate the market growth in the region. 

The European intravascular catheter market is anticipated to grow exponentially while maintaining its dominance in the second position. The market is attributed to the existence of leading industry giants and the rising prevalence of deadly diseases.

Asia Pacific region is likely to grow rapidly owing to the massive patient population suffering from chronic diseases and government initiatives for healthcare reforms.

Moreover, the Rest of the World, specifically the Middle East & Africa, is anticipated to hold least share of the global intravascular catheter market. Low per capita incomes and volatile economic reforms are some of the factors restraining the growth of this regional market.

 Market Players

The global intravascular catheter market is driven by various leading players with their product offerings and services.  Some of these major players include Cook Medical, Medtronic Inc, Johnson & Johnson, C.R. Bard, Coloplast, Getinge AB, Terumo Corporation, Boston Scientific Corporation, Edwards Life Sciences Corporation, Terumo Corporation, McKesson Medical Surgical Inc, and Smiths Medical. Product developers are major adopting latest technologies such as connected devices and smart materials to build efficient and reliable products.

Recent Updates

The U.S. FDA called out two new guidance for labeling and testing of cardiac catheterization lab devices. Under the newly issued guidance, the wires, intravascular catheters, and delivery systems with lubricious coatings will be addressed with labeling considerations specially used for vasculature. The new guidance is believed to improve the reliability of coating-related information across these products portfolios with an assurance of safety on the use of these devices in the clinical setting.

Medical Digital Imaging Devices Market 2018-2023: Growth Opportunities, Current and Projected Market Size, Recent Industry Trends and Developments

Medical Digital Imaging Devices Market Research Report Information by Type (X-Ray, Ultrasound, Nuclear Imaging, MRI), Technology (2D, B/Color, 3D/4D), End User (Hospitals, Clinics, Diagnostic Centers and others) and Region - Forecast till 2024

Market Highlights

The Global Medical Digital Imaging Devices Market held a market value of USD 12.9 Billion in 2017 and is Projected to grow at a CAGR of 7.1% over the forecast period. Medical digital imaging devices are digital devices that are used to image the body to obtain a correct diagnosis and determine future care.

Segmentation

The Global Medical Digital Imaging Devices Market has been segmented into component, deployment model, functionality, and end user.

By type, the market has been segmented into x-ray, computed tomography, ultrasound, MRI, and nuclear imaging. The x-ray segment is expected to register the highest CAGR during the forecast period due to technological advancements.

On the basis of technology, the market has been segmented into 2D, B/W, Color, and 3D/4D.

The market, by end user, has been segmented into hospitals and clinics, diagnostic centers, and others.

Access Report Details @ https://www.marketresearchfuture.com/reports/medical-digital-imaging-devices-market-7880

Key Players

Some of the prominent players in the global medical digital imaging devices market are Koninklijke Philips N.V., GE Healthcare, Siemens Healthineers, Esaote SPA, Canon Medical Systems Corporation, Hologic, Hitachi, and Shimadzu.

Regional Analysis

On a regional basis, the Americas is anticipated to dominate the global medical digital imaging devices market owing to the owing to increasing geriatric population, high prevalence of various chronic diseases, and a large number of diagnostic imaging centers. Additionally, fast adoption of technologically advanced imaging systems and increasing awareness of the benefits of early diagnosis of diseases is driving the growth of the market.

Europe accounts for the second largest market and holds a healthy share in the global medical digital imaging devices market due to major driving factors like availability of advanced treatment facilities, increasing healthcare expenditure, and flourishing medical device industry due to the presence of major market players.

Asia-Pacific is expected to be the fastest growing market, owing to the huge patient pool, a faster adaptation of healthcare technology, government initiatives to increase the healthcare quality, and availability of favorable insurance policies.

The Middle East & Africa is expected to show the least growth in the market due to some major factors such as lack of awareness, limited access and availability of treatment facilities. In the Middle East, the United Arab Emirates and Saudi Arabia is the largest market share owing to the development of the healthcare industry and the rising availability of specialty care centers.

Freeze-Drying Equipment Market Overview: Type and Applications, Trends, Industry Analysis & Forecast, 2018-2024

Freeze-Drying Equipment Research Report: by Type (Bench Top, Laboratory, Mobile, Others), by Application (Biotechnology, Pharmaceuticals, Surgical Procedures, Others), by End User (Pharmaceutical Companies, Hospitals, Others)—Forecast Till 2024

Market Highlights

The Global Freeze Drying Equipment Market held a market value of USD 2.2 billion in 2018 and is projected to grow at a CAGR of 8.9% over the forecast period.  

Freeze dryers are widely used for the prevention of heat-sensitive biological materials, pharmaceuticals, and food, among others. Nowadays, freeze drying has become a standard procedure used in the biotechnology and pharmaceutical companies for stabilizing and storing drug products. This process involves drying delicate biological and heat-sensitive drugs at low temperatures, due to which the physical structure of drugs is maintained. These processed products are used in antibodies and emergency vaccines. Increasing awareness regarding various benefits of the freeze dried product, such as enhanced efficiency related to desiccant drying and air-drying are responsible for the growth of the market during the forecast period. Moreover, the rising usage of freeze drying equipment in surgical procedures.

However, high set up & maintenance cost and increasing demand for refurbished systems from various biotechnology & pharmaceutical companies are likely to restrain the growth of the market.

Regional Analysis

On a regional basis, the Americas is anticipated to dominate the global freeze drying equipment market owing to the innovative product development and increasing investment in research and development for innovation in the region.  

Europe is expected to hold the second largest position in the global freeze drying equipment market owing to the presence of strong academic & research base and availability of funding for research in the European countries. Asia-Pacific is anticipated to be the fastest growing region in the global freeze drying equipment market owing to the shift of pharmaceutical companies to countries such as India and China, which are low-cost manufacturing regions. The Middle East & Africa has the least share of the global freeze drying equipment market.  Moreover, the major market share of the region is expected to be held by the Middle East region owing to the growing government initiatives for the healthcare sector.

Browse Complete Report :https://www.marketresearchfuture.com/reports/freeze-drying-equipment-market-7848

Segmentation

The global freeze drying equipment market has been segmented into type, application, and end user. 

By type, the market has been segmented into benchtop freeze dryers, laboratory freeze dryers, mobile freeze dryers, general purpose freeze dryers, industrial freeze dryers, and others.

Based on application, the market has been segmented into biotechnology, pharmaceuticals, surgical procedures, and others.

The market, by end user, has been segmented into pharmaceutical companies, biotechnology companies, hospitals, and others.

Key Players

Some of the prominent players in the global freeze drying equipment market are Tofflon, GEA Group Aktiengesellschaft, Labconco, Azbil Corporation, Biopharma Process Systems Ltd, Cuddon Freeze Dry, Hosokawa Micron Group, Freeze Drying Systems Pvt. Ltd, Thermo Fisher Scientific Inc., Millrock Technology, Inc., ZIRBUS technology GmbH, SP Scientific, LTE Scientific Ltd, Hitachi, Ltd, MechaTech Systems Ltd, and others.